Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...

Fieldfisher advises Kazakhstan's sovereign wealth fund on the sale of shares in Qazaq Air JSC European law firm Fieldfisher has successfully advised "Samruk-Kazyna" JSC, a US$ 81 billion Sovereign ...

Sara is the media correspondent at Axios. She is the author of the weekly Axios Media Trends newsletter and covers breaking news and analysis about the industry. Sara also is a contributor and analyst ...